Sunday, November 5, 2017
- 9:00AM-11:00AM
-
Abstract Number: 10
Arterial Events in Primary Antiphospholipid Syndrome Are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score
Antiphospholipid Syndrome Poster- 9:00AM-11:00AM
-
Abstract Number: 251
Articular Cartilage of Knee and First MTP Joint Are the Preferred Sites of Urate Crystal Deposition in Asymptomatic Hyperuricemic Individuals
Imaging of Rheumatic Diseases Poster I- 9:00AM-11:00AM
-
Abstract Number: 808
Assessing the Possible Link between Varicella Zoster Virus and Giant Cell Arteritis Using Clinical Assessment, Serology and Biopsy Antigen Detection – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Cohort
Vasculitis Poster I: Large Vessel Vasculitis- 9:00AM-11:00AM
-
Abstract Number: 499
Assessment of Early Improvement in Pain and Other ACR Components As Predictors for Achieving Low Disease Activity or Remission in Three Phase 3 Trials of RA Patients Treated with Baricitinib
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 533
Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 779
Assessment of Treatment Response By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Large Vessel Vasculitis (LVV)
Vasculitis Poster I: Large Vessel Vasculitis- 9:00AM-11:00AM
-
Abstract Number: 410
Association between Anti-Citrullinated Protein Antibody Status and the Incidence of Erosive Disease in Patients with RA
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response- 9:00AM-11:00AM
-
Abstract Number: 510
Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 327
Association of Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index with Low Bone Mineral Density in Patients with Rheumatoid Arthritis
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I- 9:00AM-11:00AM
-
Abstract Number: 164
Association of Natural Killer Cell Ligand Polymorphism, HLA-C Asn80Lys, with the Development of Anti-SSA/Ro Associated Congenital Heart Block
Genetics, Genomics and Proteomics Poster I- 9:00AM-11:00AM
-
Abstract Number: 644
Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I- 9:00AM-11:00AM
-
Abstract Number: 688
Associations between Standard Serological Markers and Different Clinical Phenotypes in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 583
Associations of Changes of Radiographic Disease and Spinal Mobility Measures in Ankylosing Spondylitis
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 718
Atherosclerotic Vascular Events in a Multinational SLE Inception Cohort: Description and Predictive Risk Factors over a 17 Year Period